ANXV is under clinical development by Annexin Pharmaceuticals and currently in Phase II for Retinal Vein Occlusion.

A multinational study led by the LHON Study Group has revealed sustained visual improvements and a favorable safety profile ...

ABBVRGX-314 is under clinical development by AbbVie and currently in Phase II for Diabetic Macular Edema. According to GlobalData, Phase II drugs for Diabetic Macular Edema have a 47% phase transition ...

Bayer announced positive topline results from the global phase III QUASAR study evaluating the efficacy and safety of aflibercept 8 mg in patients with macular edema following retinal vein occlusion ...

According to the MP Board’s date sheet for the 2024-25 session, Class 10 exams will take place in the morning shift from 9:00 ...

The company had previously reported the success of its phase III DAYLIGHT and BEACON studies evaluating tarcocimab in patients with wet AMD and retinal vein occlusion (RVO), respectively.The ...

Regeneron’s phase III QUASAR study evaluated the efficacy ... across patients with branch RVOs and those with central retinal or hemiretinal vein occlusions. In the past three months, shares ...

She is the founder and chief innovation officer of Opthea (ASX:OPT), a late-stage biopharmaceutical company developing a novel therapy to address the unmet need in treatment of retinal eye diseases.

Texas lawmakers meet with Robert Roberson III at a prison in Livingston ... But when a CT scan revealed retinal hemorrhages, a “child-abuse pediatrician” declared that this condition could ...